Literature DB >> 6120712

Impaired elimination of lorazepam following subchronic administration in two patients with renal failure.

R K Verbeeck, T B Tjandramaga, P J De Schepper, R Verberckmoes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6120712      PMCID： PMC1401964          DOI： 10.1111/j.1365-2125.1981.tb01300.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  6 in total

1.  Plasma half-life of clofibric acid in renal failure.

Authors:  E M Faed; E G McQueen
Journal:  Br J Clin Pharmacol       Date:  1979-04       Impact factor: 4.335

2.  Decreased body clearance of diflunisal in renal insufficiency--an alternative explanation.

Authors:  G Levy
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

3.  Oxazepam disposition in uremic patients.

Authors:  I Odar-Cederlöf; J Vessman; G Alván; F Sjöqvist
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1977-01

4.  Biotransformation of diflunisal and renal excretion of its glucuronides in renal insufficiency.

Authors:  R Verbeeck; T B Tjandramaga; A Mullie; R Verbesselt; R Verberckmoes; P J de Schepper
Journal:  Br J Clin Pharmacol       Date:  1979-03       Impact factor: 4.335

5.  Decreased clearance of diflunisal in renal insufficiency--an alternative explanation.

Authors:  E M Faed
Journal:  Br J Clin Pharmacol       Date:  1980-08       Impact factor: 4.335

6.  The biotransformation of drugs in renal failure.

Authors:  M M Reidenberg
Journal:  Am J Med       Date:  1977-04       Impact factor: 4.965
  6 in total
  2 in total

Review 1.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  S Dawling; P Crome
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

2.  Benzodiazepine Use During Hospitalization: Automated Identification of Potential Medication Errors and Systematic Assessment of Preventable Adverse Events.

Authors:  David Franklin Niedrig; Liesa Hoppe; Sarah Mächler; Heike Russmann; Stefan Russmann
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.